HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia.

AuthorsRadjesh J Bisoendial, G Kees Hovingh, Karim El Harchaoui, Johannes H M Levels, Sotirios Tsimikas, Kewei Pu, Aeilko E Zwinderman, Jan Albert Kuivenhoven, John J P Kastelein, Erik S G Stroes
JournalArteriosclerosis, thrombosis, and vascular biology (Arterioscler Thromb Vasc Biol) Vol. 25 Issue 9 Pg. e133-4 (Sep 2005) ISSN: 1524-4636 [Electronic] United States
PMID16127020 (Publication Type: Letter, Randomized Controlled Trial)
Chemical References
  • Amides
  • CETP protein, human
  • Carrier Proteins
  • Cholesterol Ester Transfer Proteins
  • Esters
  • Glycoproteins
  • Sulfhydryl Compounds
  • dalcetrapib
  • Cholesterol
Topics
  • Adult
  • Amides
  • Carrier Proteins (antagonists & inhibitors, metabolism)
  • Cholesterol (metabolism)
  • Cholesterol Ester Transfer Proteins
  • Esters
  • Female
  • Glycoproteins (antagonists & inhibitors, metabolism)
  • Humans
  • Male
  • Middle Aged
  • Sulfhydryl Compounds (administration & dosage)
  • Tangier Disease (drug therapy, metabolism)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: